Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care

NCT02310893 · View on ClinicalTrials.gov ↗

Study Summary

Consistent treatment with anti-retroviral therapy (ART) suppresses viral load (VL), prolonging life and improving quality of life for HIV+ persons. Suppressing VL benefits communities by reducing transmission to others. Mere availability of ART and care, however, is insufficient; the benefits of ART depend upon HIV+ persons' continuous visits to the health care provider, regular monitoring and regular delivery of medications, - known as retention in HIV care. In spite of national efforts, up to a quarter of HIV+ persons, especially low-income minorities are out of care. Innovative interventions are therefore urgently needed to maximize engagement and retention in HIV care, self-reported adherence, as well as HIV-1 RNA viral load suppression. In pursuit of these aims, the proposed study will assess outcomes of the following interventions in comparison to usual care: 1) contingency management (CM) only; 2) peer navigation (PN) only; and 3) a combined approach that integrates both CM and PN (CA) which the investigators hypothesize to be most effective in improving HIV clinical outcomes.

Conditions Studied

Interventions

  • BEHAVIORAL Contingency Management
  • BEHAVIORAL Peer Navigation
  • BEHAVIORAL Combined Contingency Management and Peer Navigation

Study Locations (6)

California

  • Center for Health Justice — Los Angeles
  • Los Angeles Sheriff's Department — Los Angeles
  • AltaMed Health Services Corporation — Los Angeles
  • Oasis Clinic — Los Angeles
  • Olive View Medical Center — Sylmar
  • Northeast Valley Health Corporation — Van Nuys

Trial Details

FieldValue
Enrollment Target 579 participants
Start Date 2016-01
Est. Completion 2020-01
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02310893

The ClinicalTrials.gov registry entry for NCT02310893 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 829 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 3 interventions — of which Contingency Management is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02310893 reports 6 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02310893 about?

NCT02310893 is a clinical study titled "Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care". Consistent treatment with anti-retroviral therapy (ART) suppresses viral load (VL), prolonging life and improving quality of life for HIV+ persons. Suppressing VL benefits communities by reducing transmission to others. Mere availability of ART and care, however, is insufficient; the benefits of ART...

What is the current status of trial NCT02310893?

This trial is currently completed. It is a NA study. The enrollment target is 579 participants. The study started on 2016-01. Estimated completion is 2020-01.

What conditions does trial NCT02310893 study?

This clinical trial studies the following conditions: HIV/AIDS. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02310893?

The interventions under investigation include: Contingency Management (BEHAVIORAL), Peer Navigation (BEHAVIORAL), Combined Contingency Management and Peer Navigation (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02310893?

This trial is sponsored by University of California, Los Angeles, which has 829 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02310893 being conducted?

This trial has 6 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial